Efficacy of Acceptance and Commitment Therapy in Reducing Disappointment, Psychological Distress, and Psychasthenia among Systemic lupus erythematosus (SLE) Patients
AbstractObjective: The aim of this study was to evaluate the efficacy of acceptance and commitment therapy (ACT) in the reduction of disappointment, psychological distress, and psychasthenia among patients with systemic lupus erythematosus (SLE). Method: This quasi-experimental study was conducted on 24 females with lupus who referred to the Rheumatoid Disease Research Center (RDRC) of Ghaem hospital in Mashhad, Iran. This study had a pretest-posttest control group design. The participants were randomly assigned into 2 groups of experimental and control. The experimental group was treated with ACT. Data were collected using the Beck’s Hopelessness Scale, Kessler’s Psychological Distress Inventory, and Krupp’s Psychasthenia Inventory. Results: Mean age and mean duration of illness were 37.25±4.61 and 5.12±2.33 years, respectively. The mean disappointment score and psychological distress in the experimental group were lower compared to those in control group at the post experimental stage (P<0.001). Moreover, there was a significant difference between the experimental and control groups in the mean scores of psychasthenia in the posttest stage (P<0.001). Conclusion: According to the obtained results of this study, the enhancement of psychological flexibility based on ACT positively affected disappointment, psychological distress, and psychasthenia among the lupus patients. Therefore, it can be concluded that this therapeutic approach could reduce psychasthenia in patients through clarification of the values.
Kozora E, Ellison MC, West S (2006) Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Care Res 2006; 55: 628-35.
Davatchi F, Jamshidi A-R, Banihashemi AT, Gholami J, Forouzanfar MH, Akhlaghi M, et al. WHO-ILAR COPCORD study (stage 1, urban study) in Iran. J Rheumatol 2008; 35: 1384-90.
Haghighi AB, Haza SG. Neuropsychiatric manifestations of systemic lupus erythematosus: Iranian experience. Ann Indian Acad Neurol 2010; 13:108.
Ramous P, Brown E, Kimberly R, Langefeld C. Genetic Factors Predisposing to Systemic Lupus Erythematosus and Lupus Nephritis. Semin Nephrol 2010; 30: 164-176.
Murray SG, Kaiser R. Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus. Arthritis Care Res 2012; 64: 1328-1333.
Mirowsky J, Ross C E. Selecting outcomes for the sociology of mental health:Issues of measurement and dimensionality. Journal of Health and Social Behavior 2002; 43: 152-7.
Lobindo, H. (2002). Nursing Research . methods critical Apprasial and utilization. Philadelphia: Mosbycom 2002;169, 174-178.
Krupp L, LaRocca N, Muir J, Steinberg A. A study of fatigue in systemic lupus erythematosus. J Rheumatol 1990; 17: 1450-2.
Lozoff B, Jimenez E, Hagen J, Mollen E, Wolf AW. Poorer behavioral and developmental outcome more than 10 years after treatment for iron deficiency in infancy. Pediatrics 2000; 105: e51.
Navarrete-Navarrete N, Peralta-Ramírez M, Sabio-Sánchez J, Coín M, Robles-Ortega H, Hidalgo-Tenorio C, et al. Efficacy of cognitive behavioural therapy for the treatment of chronic stress in patients with lupus erythematosus: a randomized controlled trial. Psychother Psychosom 2010; 79:107-15.
Bach P, Gaudiano BA, Hayes SC, Herbert JD. Acceptance and commitment therapy for psychosis: intent to treat, hospitalization outcome and mediation by believability. Psychosis 2013; 5: 166-74.
Hayes SC, Luma JB, Bond FW, Masuda A, Lilis J. Acceptance and commitment therapy: Model, processes and outcome. Behavior Research and Therapy 2006; 44: 125.
Beck AT & Steer RA (1988). Beck hopelessness scale. The Psychological Corporation, San Antonio.
Bakhshipour Roodsari A, Dejkam M, Mehryar A, Birashk B. Structural relationships between dimensions of DSM-IV anxiety and depressive disorders and dimensions of tripartite model. Iran J Psychiatry Clin Psychol 2004; 9: 63-76.
Hamidi R, Fekrizadeh Z, Azadbakht M, Garmaroudi Gh, Taheri Tanjani P, et al. Validity and reliability Beck depression inventory-II among the Iranian elderly population. J Sabzevar Univ Med Sci 2015; 22: 189-98.
Andrews G, Slade T (2001) Interpreting scores on the Kessler psychological distress scale (K10). Australian New Zealand J Public Health 25: 494-7.
Lotfi KF, Vaziri S, Arjmand S, Mousavi SM, Hashemieh M. Effectiveness of spiritual intervention on reducing distress in mothers of children with cancer. Med Ethics J 2012; 6: 173-86.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-3.
Daneshfar F, Behboodi-Moghadam Z, Khakbazan Z, Nabavi SM, Nayeri ND, Ghasemzadeh S, et al. The Influence of Ex-PLISSIT (Extended Permission, Limited Information, Specific Suggestions, Intensive Therapy) Model on Intimacy and Sexuality of Married Women with Multiple Sclerosis. Sexuality Disability 2017; 35: 399-414.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
Zettle RD. Acceptance and commitment therapy for depression. Curr Opin Psychol 2015; 2: 65-9.
Moses N, Wiggers J, Nicholas C, Cockburn J. Prevalence and correlates of perceived unmet needs of people with systemic lupus erythematosus. Patient Educ Couns 2005; 57: 30-8.
Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57: 496-500.
Meszaros ZS, Perl A, Faraone SV. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry 2012; 73: 993-1001.
Greco CM, Rudy TE, Manzi S. Effects of a stress‐reduction program on psychological function, pain, and physical function of systemic lupus erythematosus patients: A randomized controlled trial. Arthritis Care Res 2004; 51: 625-34.